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Abstract 
Background 
Estimation of pre-immunisation prevalence of HPV and distribution of HPV types is 
fundamental to understanding the subsequent impact of HPV vaccination. We describe the 
type specific prevalence of HPV in females aged 20–21 in Scotland who attended or 
defaulted from cervical screening using three specimen types; from attenders liquid based 
cytology and from defaulters urine or self-taken swabs. 
Methods 
Residual liquid based cytology samples (n = 2148), collected from women aged 20–21 
attending for their first smear were genotyped for HPV. A sample (n = 709) from women 
who had defaulted from screening was also made available for HPV testing through the use 
of postal testing kits (either urine samples (n = 378) or self-taken swabs (n = 331)). Estimates 
of prevalence weighted by deprivation, and for the postal testing kit, also by reminder status 
and specimen type were calculated for each HPV type. The distribution of HPV types were 
compared between specimen types and the occurrence of multiple high-risk infections 
examined. The influence of demographic factors on high-risk HPV positivity and multiple 
infections was examined via logistic regression. 
Results 
The prevalence of any HPV in young women aged 20–21 was 32.2% for urine, 39.5% for 
self-taken swab, and 49.4% for LBC specimens. Infection with vaccine specific types (HPV 
16, 18) or those associated with cross-protection (HPV 31, 33, 45, 51) was common. 
Individuals were more likely to test positive for high-risk HPV if they resided in an area of 
high deprivation or in a rural area. The overall distribution of HPV types did not vary 
between defaulters and attenders. Multiple infections occurred in 48.1% of high-risk HPV 
positive individuals. Excluding vaccine types the most common pairing was HPV 56 and 66. 
Conclusions 
Understanding of the pre-immunisation prevalence of HPV in young women puts Scotland in 
a prime position to assess the early effect of vaccination as the first highly vaccinated cohorts 
of individuals enter the screening programme. Differences in results with different specimen 
types must be taken into account when monitoring the impact of vaccination programmes. 
Keywords 
Human papilloma virus, Vaccination, Prevalence, Multiple infections 
Background 
The prevalence and circulating genotypes of human papillomavirus (HPV) infection in 
different study populations has recently been reported [1-3]. The incentive for such studies is 
a need for better understanding of HPV infection, but additionally to provide information to 
enable the impact of key changes in prevention, detection and management of HPV-related 
disease. Of particular importance is the introduction of HPV vaccine and increasing 
availability and use of HPV tests within cervical screening programmes. 
A better understanding of the natural history and epidemiology of HPV feeds into models of 
vaccine impact and cost effectiveness to inform decision-making on HPV immunisation and 
future changes to cervical screening. Defining a baseline against which to monitor the impact 
of vaccination provides a means to measure the earliest expected change - which is a decrease 
in the prevalence of vaccine-specific HPV. 
The range of study populations, severity and types of associated pathology in target age 
groups means that few of the studies on HPV prevalence are generalizable. Estimates of HPV 
prevalence in the general population often come from studies that consider samples from 
cervical screening programmes due to ease of sampling and availability of a link to 
cytology/disease status [1,3]. These frequently include women across a wide age range. Such 
studies may however introduce a bias if the prevalence of HPV in those who default from 
screening differs substantially from those who attend. In Scotland, attendance at cervical 
screening is high overall (71.2% in the previous 3.5 years in 2012–13) but is lower in those 
aged 20–24 (53.5%) [4]. 
For an estimate of Cervarix® vaccine impact it is important to ascertain the effect of the 
vaccination programme on the whole population, with particular focus on the age group 
where these changes will be observed first. In Scotland, cervical screening currently begins at 
age 20, therefore it is one of the few countries in the world able to detect early impacts of the 
vaccine which was introduced in September 2008. The vaccine was implemented as routine 
in-school vaccination of those aged 12–13 with a catch-up campaign for all those aged 13–17 
years old at the time [5] and achieved sustained high uptake [6]. In order to monitor the 
immunisation programme, a complementary, systematic national public health HPV 
surveillance programme was implemented in Scotland. 
This paper describes the methods used to establish representative population-based estimates 
of HPV prevalence in unvaccinated women aged 20–21 in Scotland. By using two sampling 
methods, we examined the prevalence of HPV in those who attended for cervical screening 
and in those who did not and the distribution of HPV types detected. We aimed to improve 
the representativeness of the baseline HPV prevalence estimates and compare patterns 
between those who default from and those who attend for screening. In addition, we 
examined the effect of different specimen types upon estimates of HPV prevalence. The 
occurrence of multiple HPV types is examined with particular emphasis on co-incidence of 
high-risk vaccine types (16 and 18) with other high-risk types. Such estimates are 
fundamental to understanding the impact of the HPV vaccination in the general population, 
while validating the public health approach taken in Scotland. 
Methods 
Sampling and surveys 
Scotland has a population of approximately 5.3 million [7] and an organised cytology based 
cervical screening programme. Screening age is currently 20 to 60 years and women are first 
invited to attend after their 20th birthday. Following this invitation, if they do not attend they 
are sent two reminder invitations at three monthly intervals and are classified as “defaulters” 
if they have not attended by three months following the second reminder. All women in 
Scotland eligible for cervical screening are recorded in the Scottish Cervical Screening Call 
and Recall System (SCCRS), a population-based information technology system, which 
supports the programme and contains pathology results, recall and management information. 
Population attending for screening 
In 2009, anonymised residual liquid based cytology (LBC) samples from young women aged 
20–21 years attending their first screening appointment were collected from all (11) NHS 
cytopathology laboratories in Scotland, which have national coverage. To achieve the desired 
sample size of 2,000 specimens, each laboratory collected over a two month period, staggered 
throughout the year, and selected samples from women born after 1st January 1988, with the 
number of samples collected proportionate to the population which the laboratory served. 
Population defaulting from screening 
Self-taken specimens were obtained using a postal testing kit (PTK) for women who 
defaulted from attending their first screening appointment in 2008. From an anonymised data 
file of 15367 women, 5500 were randomly selected across all Health Board administration 
areas ensuring a geographically representative sample. Half of the randomly selected women 
were sent a urine test kit and half a self-taken vaginal swab kit. Details of the methodology 
are reported elsewhere [8]. 
Data and linkage 
All LBC, swab and urine specimens were labelled with a study identification number. The 
study ID was separately linked to SCCRS data using the unique Community Health Index 
identifier. Geographical datazone, derived from postcode of residence, was attributed to each 
record. HPV results were matched to each record and all personal identifiable information 
was then removed from the dataset prior to statistical analysis. The Scottish Index of Multiple 
deprivation (SIMD) quintiles (1: Most deprived; 5: Least deprived) and urban–rural six-fold 
classification were extracted from the Scottish Neighbourhood Statistics 
(http://www.sns.gov.uk) and linked to the dataset via datazone. The percentage of non-white 
residents in each datazone (“white” defined as White Scottish, White Irish, White Other 
British or Other White according to the ethnicity question in the 2001 census) was obtained 
from http://www.scrol.gov.uk/scrol/warehouse/NewWards_ER_OA.jsp for the census output 
areas and the aggregated up to data zones. As high concentrations of non-white individuals 
are clustered within a small number of datazones, this variable was categorised into quintiles. 
As a large proportion of individuals reside in urban classes 1(large urban) or 2 (other urban), 
reflecting the population distribution in Scotland, the urban–rural classification was recoded 
so that categories 3 (accessible small towns) and 4 (remote small towns) are combined to 
form a small town class and 5 (accessible rural) and 6 (remote rural) a rural class giving a 
suitable number of specimens in each level. 
HPV testing 
All LBC samples were collected in ThinPrep media whereas swab samples were collected 
within M4RT media (Remel Products, Thermo Scientific, Lenexa, KS, USA). Urine was 
collected in 20 ml universals without any stabilisation or preservative buffer. A 5 ml aliquot 
of urine samples was centrifuged and the pellet washed twice with Phosphate Buffered Saline 
(PBS) before reconstitution in 1 ml of PBS prior to extraction. Self-taken swabs and residual 
LBC samples were vortexed and a 1 ml aliquot used for extraction. Automated extraction for 
both sample types was performed used the MDX media Kit (Qiagen Ltd, Manchester, UK). 
As this automated platform incorporates batch extraction in a 12 × 8 grid format 10% of all 
samples constituted HPV negative internal quality control material, the grid reference of 
which varied across batches as a contamination check. In addition previously tested positive 
control material was also included within each batch. HPV amplification and genotyping was 
performed using biotinylated GP5 + 6+ primers, prior to downstream genotyping using the 
Digene HPV Genotyping RH test (Qiagen). This assay is capable of detecting 18 high-risk or 
putatively high-risk types according to current IARC classification [9], specifically the 12 
types in Group 1 with “carcinogenic” status: HPV 16,18,31,33,35,39,45,51,52,56,58,59, the 
single type in Group 2A with “probably carcinogenic” status: HPV 68 and 6 types from 
Group 2B with “possibly carcinogenic” status: HPV 26,53,66,73,82. Other HPV types, 
including types 6 and 11 are not differentiated but identified as “HPV other”. 
Four grouped definitions were created; positive for any HPV type, positive for the vaccine 
types 16 and 18, positive for the HPV types where some vaccine cross-protection has been 
demonstrated – HPV 31, 33, 45 and 51 [10] and finally, positive for any high-risk type 
(Group 1 and Group 2A [9]). In addition, individuals with multiple infections (infected with 
more than one HPV type) were identified. 
Statistical analysis 
The sample size was determined by the design of the long-term surveillance system, where 
the primary aim is to detect changes in HPV positivity over time. 2000 LBC samples were 
collected from unvaccinated women in the baseline year. The target sample size in the postal 
testing kit study was 1000 in order to give a 90% power to detect differences in HPV 
positivity of ± 6% points between screening defaulters and attenders. The actual sample 
achieved was 709, from a 13.2% response rate to the study, see [8] for more details. 
To obtain representative estimates of HPV prevalence from the PTK sample, weights were 
calculated by raking which matches marginal distributions of a survey sample to known 
population margins [11]. Observations were weighted according to the distribution of SIMD, 
specimen type (urine or swab) and reminder status in the PTK sample. The LBC samples 
obtained were weighted proportionately to the distribution of SIMD in the cohort of young 
women aged 20–21 years available for sampling – the SCCRS extract. 
The discrepancy in the distribution of HPV types detected by each of the specimen types was 
assessed using a simulation test using 1000 simulations as described in Cuschieri et al. [12]. 
The distribution of HPV types for each specimen type was compared to the overall 
distribution of HPV types from all specimens. The simulated p-value was calculated from the 
proportion of simulations with a discrepancy greater that that observed in the data. In such a 
way it can be established if different patterns in HPV type positivity are found between the 
specimen types and therefore between screening defaulters and attenders. 
The odds of HPV infection given urban/rural classification, the proportion of non-white 
residents and SIMD of the datazone of residence were estimated in both a univariable and 
multivariable model using survey weighted logistic regression adjusting for the specimen 
type – LBC, self-taken swab or urine – and using a linear trend test for the ordered variables. 
Interactions between each of SIMD, the proportion of non-white residents and urban/rural 
classification with specimen type were examined. 
All analysis was carried out using the statistical software, R version 2.12.2 [13] with use of 
the survey library [14]. 
Ethics 
Self-taken sample collection was approved by West of Glasgow Ethics Committee 
[09/S0703/13]. National surveillance has been approved through the NHS National Clinical 
Governance committees and Caldicott Guardians at individual NHS Boards. Data linkage of 
information was approved by the NHS National Services Scotland (NSS) CHI advisory 
group. 
Results 
Demographics 
Characteristics of the cervical screening and self-sampling groups are shown in Table 1. HPV 
test results were available for 2148 residual LBCs and 709 self-taken samples from defaulters 
consisting of 331 swab and 378 urine samples. SIMD could not be linked to 86 of the LBC 
samples which were subsequently excluded from the analysis. 
Table 1 Comparison those attending their first screening appointment, defaulters who provided a self-taken sample, and the SCCRS 
cohort 
 Attenders Defaulters Cohort 
Liquid based cytology samples Self-taken samples Extract of registered women from SCCRS 
 n % n % n % 
SIMD       
1: Most deprived 470 22.8 145 20.5 9204 22.3 
2 481 23.3 125 17.6 8689 21.1 
3 400 19.4 129 18.2 7515 18.2 
4 333 16.1 147 20.7 7262 17.6 
5: Least deprived 378 18.3 163 23.0 8545 20.7 
Proportion of non-white residents in datazone       
Q1 [0.0%-0.4%) 458 22.2 151 21.3   
Q2 [0.4%-1.0%) 450 21.8 137 19.3   
Q3 [1.0%-2.0%) 431 20.9 135 19.0   
Q4 [2.0%-5.3%) 398 19.3 136 19.2   
Q5 [5.3%-65.6%) 325 15.8 150 21.2   
Datazone urban/rural       
1: large urban 991 48.1 339 47.8   
2: other urban 626 30.4 196 27.6   
3-4: accessible/remote small towns 204 9.9 83 11.7   
5-6: accessible/remote rural 241 11.7 91 12.8   
SIMD is the Scottish Index of Multiple Deprivation. The proportion of non-white residents in each area is derived from 2001 census data. 
SCCRS is the Scottish Cervical Call/Recall System which all women eligible for screening in Scotland are recorded on. 
Weighted prevalence estimates and type distribution 
The prevalence of any HPV was 32.2% for the urine, 39.5% for the self–taken swab, and 
49.4% for the LBC samples (Table 2). Type 16 and/or 18 was detected in 10% of the urines, 
compared with 16.6% of the self-taken swabs and 23% of the LBCs. For any high-risk HPV, 
the respective prevalence estimates were 19.1%, 29.1% and 41.2%, for high-risk types 
excluding 16 and 18, 13.2%, 20.6% and 32.3% and for high-risk types excluding the cross 
protection types, 8%, 11.2% and 21.5%. The unadjusted odds of detection of high-risk HPV 
positivity was reduced for the self–taken swabs compared to the LBC samples (OR = 0.59 
(95% CI: 0.45, 0.76), p = 0.001) and similarly for the urine samples (OR = 0.34 (95% CI: 
0.26, 0.44), p < 0.0001) (Table 3). 
Table 2 Weighted prevalence of HPV and corresponding 95% confidence interval (CI) 
stratified by sample type 
 Urine Self-taken swab LBC 
HPV type Prevalence 95% CI Prevalence 95% CI Prevalence 95% CI 
Any HPV 32.2% (27.4, 
37.0)% 
39.5% (34.2, 
44.9)% 
49.4% (47.2, 
51.5)% 
HPV 16 or 18 10.0% (6.8, 
13.1)% 
16.6% (12.5, 
20.7)% 
23.0% (21.2, 
24.8)% 
HPV 31 or 33 or 45 or 51 9.3% (6.4, 
12.3)% 
13.5% (9.7, 
17.3)% 
19.1% (17.4, 
20.8)% 
Any high-risk HPV 19.1% (15.0, 
23.1)% 
29.1% (24.1, 
34.1)% 
41.2% (39.1, 
43.4)% 
High-risk excluding HPV 
16 or 18 
13.2% (9.8, 
16.7)% 
20.6% (16.2, 
25.0)% 
32.3% (30.2, 
34.3)% 
High-risk excluding HPV 
16, 18, 31, 33, 45 or 51 
8.0% (5.2, 
10.8)% 
11.2% (7.7, 
14.7)% 
21.5% (19.7, 
23.2)% 
PTK samples were weighted by SIMD, specimen type and reminder status. LBC samples 
were weighted by SIMD. 
Table 3 Unadjusted and adjusted odds of infection with any high-risk HPV type for each specimen type, SIMD and urban/rural 
classification 
 Unadjusted OR 95% CI Adjusted OR 95% CI 
Specimen type     
LBC 1 - 1 - 
Self-taken swab 0.59 (0.45, 0.76) 0.58 (0..45, 0.75) 
Urine 0.34 (0.26, 0.44) 0.33 (0.25,0.44) 
SIMD     
1: Most deprived 1  1  
2 0.78 (0.62, 0.99) 0.73 (0.57, 0.93) 
3 0.96 (0.75, 1.22) 0.87 (0.67, 1.12) 
4 0.78 (0.60, 1.01) 0.69 (0.53, 0.91) 
5 Least deprived 0.64 (0.49, 0.82) 0.62 (0.48, 0.80) 
Urban rural classification     
1: Large urban 1 - 1 - 
2: Other urban 1.38 (1.15, 1.67) 1.41 (1.16, 1.71) 
3-4: accessible/remote small towns 1.19 (0.90, 1.57) 1.25 (0.94, 1.66) 
5-6: accessible/remote rural 1.60 (1.24, 2.07) 1.68 (1.28, 2.20) 
Proportion of non-white residents in datazone     
Q1 [0.0%-0.4%) 1 -   
Q2 [0.4%-1.0%) 0.89 (0.70, 1.14)   
Q3 [1.0%-2.0%) 0.84 (0.66, 1.08)   
Q4 [2.0%-5.3%) 0.72 (0.56, 0.92)   
Q5 [5.3%-65.6%) 0.56 (0.43, 0.73)   
Type specific analyses (Figure 1) by specimen type demonstrate that type 16 is the most 
predominant HPV type with LBC samples having the highest prevalence (18.1% 95% CI 
(16.4, 19.8)%). Generally the prevalence for each HPV type is highest for LBC samples, 
followed by self-taken swabs and then urine. 
Figure 1 Weighted estimates of HPV prevalence stratified by sample type. 
Comparison of the distributional spread of HPV types, excluding the “HPV other” category, 
showed that the aggregated PTK sample (urines and swabs together) did not have a 
significantly different distribution compared to the LBC samples (p = 0.470) indicating little 
difference in HPV types between those who defaulted and those who attended screening. 
Within the PTK sample, urine and self-taken swabs were found to have a different 
distribution of types (p = 0.032) with higher detection of HPV types 16, 56, 18, 51, and 45 in 
the self-taken swabs compared to urine. 
Which factors influence high-risk HPV positivity? 
Adjusting for the effect of specimen type, urban/rural classification, SIMD and proportion of 
non-white residents were all found individually to have a statistically significant linear trend 
effect on positivity (p-value for urban/rural, p = 0.0029, proportion of non-white residents 
quintile, p < 0.0001, SIMD p = 0.002). No significant interactions were found 
(SIMD*specimen type, p = 0.119, proportion of non-white residents*specimen type, p = 
0.08, urban/rural*specimen type, p = 0.858). In the multivariable model, the linear effect of 
quintile of non-white residents became statistically non-significant (p = 0.497) and was 
removed from the model. 
The reduced model showed a linear effect of SIMD (p = 0.00071) and of urban/rural 
residence (p = 0.0014) and a difference between the specimen types (p < 0.0001). The 
adjusted odds ratios indicate that individuals in SIMD4 and SIMD5 (least deprived) har lower 
odds of high-risk HPV positivity than those in SIMD1 (most deprived) (Table 3). The odds of 
any high-risk HPV infection for individuals in rural areas (classes 5–6) were 1.68 times more 
than those in the large urban areas (class 1). There was an increase in the odds of high-risk 
HPV positivity for those living in other urban areas (class 2) in comparison to large urban 
areas (adjusted OR = 1.41(95% CI: 1.16, 1.66)). There is a strong association between 
deprivation and urban rural status. Of those individuals from large urban areas nearly 30% 
were highly deprived (SIMD1) compared to 22% overall while among those who live in 
remote rural areas there are few in SIMD 1 or 5. This association had no impact on the ORs 
of being high-risk HPV positive implying that the SIMD gradient associated with HPV 
positivity is the same in large urban areas as in other areas (interaction test p = 0.477). 
Multiple high-risk HPV infections 
Overall, 1271 individuals tested positive for any HPV and 1021 for a high-risk HPV type. Of 
these 1021, 491 (48.1%) were infected with more than one high-risk type, 17.7% of the total 
samples (n = 2771). Of those infected with more than one high-risk HPV type, 58.4% were 
infected with two types, 25.6% with three, 9.9% with four, 4.3% with five and 1.8% with 
more than five. The maximum number found in an individual was 8 high-risk HPV types. 
HPV types most frequently found with the vaccine specific types are summarised in Figure 2. 
The vaccine specific pairing of types 16 and 18 occurred in 10.8% of those with multiple 
high-risk types. The most common pairings with type 16, excluding type 18, were high-risk 
HPV types 31, 56, 33 and 59. Types 31, 56 and 59 were also the most common with type 18. 
Limiting the analysis to the non-vaccine types, the most common pairing was types 56 and 66 
(5.4% of those with multiple types). 
Figure 2 All high-risk HPV types occurring with HPV 16 (top panel, excluding HPV18) 
and HPV 18 (bottom panel, excluding HPV16) in those individuals with multiple high-
risk HPV infections (n = 491). 
Amongst those positive for any high-risk HPV no significant association was found between 
SIMD quintile (p = 0.76), urban/rural status (p = 0.46) or ethnicity quintile (p = 0.62) and the 
odds of having a multiple high-risk HPV infection compared to a single high-risk HPV. 
Differences were found in the odds of detecting multiple high-risk HPV infection between 
specimen types (p = 0.016) with fewer multiple infections detected in self-taken samples in 
line with the reduced sensitivity of these collection methods (Self taken swab OR = 0.61 
(95%CI 0.4, 0.96); Urine OR = 0.60 (0.37, 0.98)). 
Discussion 
It is a challenge to measure the prevalence of HPV since, unlike many other infections, there 
is comparatively little diagnostic type specific HPV testing which would allow surveillance 
through existing data sets such as public health notification systems. Many prevalence studies 
are restricted to populations that attend for cervical screening, those under investigation for 
cervical abnormalities detected or those accessing sexual health services [15,16]. In this study 
of unvaccinated 20 and 21 year olds in Scotland eligible for their first cervical screen, we 
have obtained samples from both those attending screening and defaulters, albeit the latter 
limited by a low response rate to the PTK −13.2% [8], in order to estimate pre-immunisation 
HPV prevalence in this cross-section of the population. 
Our original aim was to compare HPV positivity among attenders for screening and 
defaulters but this comparison is confounded with specimen type. The difference in 
prevalence of 39.5% from the self-taken swab and 49.4% from the nurse-taken LBC swab 
suggests that those who do not attend for screening have a lower prevalence. This is unlikely 
to be the case. As this study shows a consistent gradient of increasing HPV positivity with 
increasing SIMD deprivation levels and the screening defaulters have a greater 
preponderance of SIMD1 (deprived) individuals compared to those who attend for screening 
[8] we would have anticipated greater HPV positivity among the defaulters. We therefore 
conclude that the differences are likely due to the different specimen types and the baseline 
HPV patterns within the defaulter population is likely to be similar to the attenders - 
consequently the on-going assessment of the impact of HPV vaccination in Scotland will be 
based on LBC samples. 
HPV infection was common in this population of young women and multiple infections were 
detected in approximately half of all HPV positive samples. Baseline pre-immunisation levels 
of the vaccine specific types were high, with HPV 16 the more common than HPV 18. The 
aggregate occurrence of non-vaccine types, in particular those deemed to be high-risk, is 
more prevalent than the vaccine specific types and our results are comparable to those of 
other recent UK based studies [15,17]. 
Individual risk factors associated with HPV infection status, such as sexual activity and 
ethnic minority background [17], were not available. Linkage allowed assignment to each 
individual of SIMD, urban/rural designation and proportion of non-white residents. These 
should not be interpreted as individual attributes in this study. In a fully adjusted model, 
significant association with high-risk HPV positivity was found with increasing deprivation 
and rural classification. Although there has been some indication that individuals in rural 
areas may have higher levels of risky sexual behaviour [18,19] this is not well evidenced. 
However, this result is in accordance with the findings from the school based prevalence 
study carried out in Scotland which showed increasing HPV positivity with increasing levels 
of deprivation and in rural schools [20]. 
There was no overall difference in the distribution of HPV types between the aggregate PTK 
sample and the LBC samples, implying that HPV patterns are similar in both populations. In 
terms of prevalence estimates, urine and self-taken swabs are not comparable to LBC samples 
nor to each other but if used consistently could allow trends to be monitored for surveillance 
purposes especially in those defaulting from screening [21]. 
Multiple high-risk HPV infections were common, with around half of those infected having 
more than one type detected. Quantifying and defining the extent of multiple HPV infection 
is important as it may limit or enhance the effectiveness of the immunisation programme. 
With regard to the former, any increase in the prevalence of non-vaccine high-risk genotypes 
due to type replacement rather than unmasking could erode the programme’s cost-
effectiveness. On the other hand, cross protection of the vaccine may somewhat mitigate 
against type replacement, particularly against 31, 33 & 45. There is some evidence suggesting 
that Cervarix® may confer relatively high levels of cross-protection [22]. 
Sexual behaviour has been shown to influence the risk of having multiple HPV infections and 
overall there are differences between younger and older women in factors that influence high-
risk HPV positivity [23]. There is a slight age gap between the two populations of young 
women sampled (LBC and PTK). The LBC data were derived from young women aged 20 
and 21 in 2009 (approximate 50:50 split between the ages) whilst the PTK were sent to 
women reaching 21 in 2008. There may have been a secular increase in overall HPV 
prevalence in the intervening time period. However, any effect that this may have had is 
likely to be minimal given that HPV infections can persist and given that we are measuring 
prevalence rather than incidence. 
Conclusions 
Our study estimated the prevalence of HPV in unvaccinated young women living in Scotland. 
This study was essential in order to determine the baseline burden of HPV infection before 
vaccination. Specimens were tested using the same HPV assay at the same testing laboratory 
ensuring consistency of results. Although the varying sensitivity of the different specimen 
types in detecting HPV does not allow direct comparison between the prevalence of HPV in 
those attending screening and those defaulting, the similarity in the type specific HPV 
prevalence distributions and the consistent differences in the prevalence estimates obtained 
from the three sample types suggest that the infection pattern between defaulters and 
attenders is unlikely to be substantially different. 
Due to the low uptake of defaulters to the PTK [8] the effectiveness of this tool for 
surveillance of changes in HPV prevalence post vaccination is limited and is therefore 
unlikely to be repeated. However, give the high and equitable uptake of HPV vaccination 
achieved in young women in Scotland [6], limiting surveillance to testing samples from those 
attending screening is likely to estimate accurately the effect of the vaccination on HPV 
prevalence in young women overall. 
We are now in a prime position to ascertain the early effects of the HPV vaccine on young 
women who were part of the initial vaccination campaign and who were called for cervical 
screening from 2010. Having a systematic surveillance programme which has included the 
characterisation of a pre-vaccine baseline will allow us to robustly determine these effects. 
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